Fasken represented Amplitude Ventures Capital in its financing of Giiant Pharma Inc., a Montreal-based preclinical-stage biotech company. This investment supports the development of its precision delivery technology platform in gastroenterology.
This transaction is part of Amplitude’s strategy to support the growth of world-class Canadian companies specializing in precision medicine. Amplitude had also launched a C$200 million venture capital fund with this in mind in November 2019.
This C$13.5 million financing also brought together the following investors: Genesys Capital, Fonds de solidarité FTQ, Fonds II d’AmorChem, Theodorus Investment Fund, Anges Québec, and other angel investors.
A Fasken team made up of Jean-François Séguin, Dan Su and Jean-Nicolas Delage represented Amplitude on this matter.
This transaction is part of Amplitude’s strategy to support the growth of world-class Canadian companies specializing in precision medicine. Amplitude had also launched a C$200 million venture capital fund with this in mind in November 2019.
This C$13.5 million financing also brought together the following investors: Genesys Capital, Fonds de solidarité FTQ, Fonds II d’AmorChem, Theodorus Investment Fund, Anges Québec, and other angel investors.
A Fasken team made up of Jean-François Séguin, Dan Su and Jean-Nicolas Delage represented Amplitude on this matter.
Jurisdiction
- Québec